bexarotene has been researched along with Hypertriglyceridemia in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alia, P; Cabello, I; Cervigón, I; Estrach, T; Fernandez-de-Misa, R; Gallardo, F; Izu, R; Morillo, M; Muniesa, C; Ortiz-Brugues, A; Ortiz-Romero, PL; Peñate, Y; Perez-Farriols, A; Pintó, X; Román, C; Servitje, O | 1 |
| Hamada, T; Iwatsuki, K; Kawai, K; Kiyohara, E; Matsushita, S; Nagatani, T; Ohtsuka, M; Saida, T; Setoyama, M; Sugaya, M; Tani, M; Tokura, Y; Tsuboi, R; Yonekura, K | 1 |
| Atmaca, H; Islek, I; Sentürk, N | 1 |
| Bardés, I; Cabello, I; Corbella, X; Pintó, X; Servitje, O | 1 |
| Bair, SM; Cherpelis, BS; Fenske, NA; Glass, LF; Marquez, CB; Smithberger, EE; Wenham, RM | 1 |
| Ardizzoni, A; Di Nuzzo, S; Musolino, A; Panebianco, M; Santini, M; Zendri, E | 1 |
| Dziewanowska, ZE; Hermann, TW; Luo, W; Malo, N; Marschke, KB; Meglasson, MD; Negro-Vilar, A; Ng, SC; Sanders, JM; Schork, NJ; Tooker, P; Zapala, MA; Zhang, J | 1 |
| Alvarado, CS; Busam, KJ; Hale, GA; Horwitz, S; Jaffe, ES; Kim, YH; Mehta, N; Myskowski, P; Pulitzer, M; Wayne, AS; Zwerner, J | 1 |
| Chu, Q; Dunlop, D; Hao, D; Jacobs, CD; Leighl, N; Lopez-Anaya, A; Middleton, G; Ramlau, R; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA; Zatloukal, P | 1 |
| Hahtola, S; Ranki, A; Väkevä, L | 1 |
| Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS | 1 |
| Apisarnthanarax, N; Breuer-Mcham, J; Duvic, M; Talpur, R; Ward, S | 1 |
| de Jong, EM; De Weert, J; Franssen, ME; Lambert, J; Roseeuw, DI; Smit, JV; Stevens, VJ; van De Kerkhof, PC; Yocum, RC | 1 |
| Bedor, M; Bisaccia, S; Doyle, LA; Edelman, MJ; Hausner, P; Kalra, K; Kendall, J; Smith, R | 1 |
| Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S | 1 |
| Bolejack, V; Crowley, J; Ekstrand, B; Ghalie, R; Govindan, R; Jaunakais, D; Kennedy, P; Sandler, A; Schwartzberg, L; Williams, C | 1 |
| Blumenschein, GR; Dziewanowska, ZE; Gatzemeier, U; Jotte, RM; Khuri, FR; Le Treut, J; Miller, WH; Negro-Vilar, A; Sun, SL; von Pawel, J; Zhang, JK | 1 |
| Dziewanowska, ZE; Gottfried, M; Jassem, J; Negro-Vilar, A; Negro-Vilar, R; Orlov, SV; Pereira, JR; Rahal, S; Ramlau, R; Schwarzenberger, P; Temperley, G; Zatloukal, P; Zhang, JK | 1 |
| Heyman, RA; Hoener, P; Jow, L; Mukherjee, R; Paterniti, JR; Strasser, J | 1 |
| Dallongeville, J; Fruchart, JC; Gervois, P; Kooistra, T; Kosykh, V; Princen, HM; Staels, B; Torra, IP; Vu-Dac, N | 1 |
| Duvic, M | 1 |
1 review(s) available for bexarotene and Hypertriglyceridemia
| Article | Year |
|---|---|
Current treatment of Cutaneous T-Cell Lymphoma.
Topics: Administration, Oral; Administration, Topical; Anticarcinogenic Agents; Apoptosis; Bexarotene; Biopsy; Carmustine; Disease Progression; Drug Eruptions; Humans; Hypertriglyceridemia; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Neoplasm Staging; Prognosis; PUVA Therapy; Retinoids; Sezary Syndrome; Tetrahydronaphthalenes; Vitamin D | 2001 |
9 trial(s) available for bexarotene and Hypertriglyceridemia
| Article | Year |
|---|---|
Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma: The results of a phase 2 study (B-1201).
Topics: Adult; Antineoplastic Agents; Bexarotene; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypothyroidism; Japan; Leukopenia; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Male; Mycosis Fungoides; Neoplasm Staging; Neutropenia; Skin Neoplasms; Time Factors; Young Adult | 2019 |
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atorvastatin; Bexarotene; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Tetrahydronaphthalenes; Treatment Outcome | 2012 |
A phase II multicenter clinical trial of systemic bexarotene in psoriasis.
Topics: Adult; Bexarotene; CD4 Antigens; Female; Humans; Hypertriglyceridemia; Male; Psoriasis; Quality of Life; Secondary Prevention; Tetrahydronaphthalenes; Treatment Outcome | 2004 |
Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome | 2005 |
Bexarotene and erlotinib for aerodigestive tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Capsules; Carcinoma, Non-Small-Cell Lung; Exanthema; Female; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Survival Analysis; Tetrahydronaphthalenes | 2006 |
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Neoplasm Transplantation; Paclitaxel; Survival Analysis; Tetrahydronaphthalenes | 2008 |
Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Survival Rate; Tetrahydronaphthalenes; Triglycerides; Vinblastine; Vinorelbine | 2008 |
Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.
Topics: Adult; Apolipoprotein C-III; Apolipoproteins C; Benzoates; Bexarotene; Carcinoma, Hepatocellular; Cells, Cultured; Dimerization; Double-Blind Method; Gene Expression Regulation; HeLa Cells; Humans; Hypertriglyceridemia; Isotretinoin; Liver; Liver Neoplasms; Male; Mutagenesis, Site-Directed; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Regulatory Sequences, Nucleic Acid; Retinoid X Receptors; Retinoids; Tetrahydronaphthalenes; Transcription Factors; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 1998 |
12 other study(ies) available for bexarotene and Hypertriglyceridemia
| Article | Year |
|---|---|
Association of APOA5 and APOC3 Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apolipoprotein A-V; Apolipoprotein C-III; Bexarotene; DNA; Female; Follow-Up Studies; Genotype; Humans; Hypertriglyceridemia; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Polymorphism, Genetic; Retrospective Studies; Severity of Illness Index | 2018 |
Reversible pituitary insufficiency due to bexarotene therapy in a patient with mycosis fungoides.
Topics: Adrenal Insufficiency; Anticarcinogenic Agents; Bexarotene; Humans; Hypertriglyceridemia; Hypogonadism; Hypopituitarism; Hypothyroidism; Male; Middle Aged; Mycosis Fungoides; Tetrahydronaphthalenes | 2014 |
Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Chemotherapy, Adjuvant; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipid Metabolism; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; Tetrahydronaphthalenes | 2017 |
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
Topics: Adenocarcinoma, Papillary; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bexarotene; Carboplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Humans; Hypertriglyceridemia; Hypothyroidism; Keratoacanthoma; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Tetrahydronaphthalenes | 2009 |
Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids.
Topics: Adult; Aged; Bexarotene; Contraindications; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 2009 |
Identification of polymorphisms associated with hypertriglyceridemia and prolonged survival induced by bexarotene in treating non-small cell lung cancer.
Topics: Bexarotene; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Clinical Trials, Phase III as Topic; DNA; Female; Genetic Predisposition to Disease; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Tetrahydronaphthalenes | 2011 |
Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Child; Child, Preschool; Diabetes Mellitus, Type 1; Disease-Free Survival; Female; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Panniculitis; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Young Adult | 2012 |
Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticarcinogenic Agents; Aspartate Aminotransferases; Bexarotene; Combined Modality Therapy; Finland; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypothyroidism; Liver; Lymphoma, T-Cell, Cutaneous; Middle Aged; Neoplasm Staging; Neutropenia; Retrospective Studies; Skin Neoplasms; Tetrahydronaphthalenes | 2012 |
U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Topics: Adult; Amylases; Anticarcinogenic Agents; Bexarotene; Blood Cell Count; Blood Glucose; Cholesterol, HDL; Clinical Protocols; Drug Administration Schedule; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Liver Function Tests; Lymphoma, T-Cell, Cutaneous; Musculoskeletal Pain; Pancreatitis; Pregnancy; Pregnancy Complications; Skin Neoplasms; Tetrahydronaphthalenes; Thyrotropin; Thyroxine | 2013 |
Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Topics: Algorithms; Anticarcinogenic Agents; Bexarotene; Dermatitis, Exfoliative; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypothyroidism; Middle Aged; Mycosis Fungoides; Photopheresis; Prospective Studies; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 2002 |
RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo.
Topics: Acyl-CoA Oxidase; Animals; Bexarotene; Cholesterol, HDL; Drug Combinations; Female; Gemfibrozil; Gene Expression Regulation; Hypertriglyceridemia; Hypolipidemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Oxidoreductases; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Signal Transduction; Tetrahydronaphthalenes; Transcription Factors; Transcriptional Activation; Triglycerides | 1998 |
Bexarotene (Targretin) for cutaneous T-cell lymphoma.
Topics: Bexarotene; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Fees, Pharmaceutical; Half-Life; Humans; Hypertriglyceridemia; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Receptors, Retinoic Acid; Retinoids; Tetrahydronaphthalenes | 2000 |